Purpose:  To determine if treatment with motesanib AMG 706 in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in patients with advanced NSCLC (non-small cell lung cancer).

lungcancer3952

Inclusion Criteria:

• Histologically confirmed, unresectable stage 111B with pericardial or pleural effusion or stage IV or recurrent NSCLC.
• Ability to take oral medications

Exclusion Criteria:

• Any prior chemotherapy for advanced NSCLC
• Pregnant or breastfeeding woman.